32 results on '"Hedlund, Per Olov"'
Search Results
2. PSA Kinetics Provide Improved Prediction of Survival in Metastatic Hormone-Refractory Prostate Cancer
3. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from the scandinavian prostate cancer group study 5
4. Clinical Research Done by the Scandinavian Prostate Cancer Group during the First 20 Years
5. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naive bone-metastatic prostate cancer
6. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality
7. DEFERRED TREATMENT OF LOCALLY ADVANCED NONMETASTATIC PROSTATE CANCER: A LONG-TERM FOLLOWUP
8. The effects of low-dose heparin treatment on patients undergoing transvesical prostatectomy
9. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostate cancer
10. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer : Evaluation of cardiovascular events in a randomized trial
11. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer:evaluation of cardiovascular events in a randomized trial
12. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer : part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
13. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
14. Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients.
15. Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.
16. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from Scandinavian Prostate Cancer Group Study 5.
17. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial
18. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
19. Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer - Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
20. Side effects of endocrine treatment and their mechanisms: Castration, antiandrogens, and estrogens
21. The Scandinavian Prostatic Cancer Group: A Short Review of its History and Work
22. Deferred treatment of clinically localized low-grade prostate cancer: Actual 10-year and projected 15-year follow-up of the karolinska series
23. Evaluation and follow-up of patients with n1-3 m0 or nxm1 prostate cancer in phase iii trials
24. Deferred Treatment of Clinically Localized Low Grade Prostate Cancer: The Experience From A Prospective Series at The Karolinska Hospital
25. The Prognostic Value of Modal Deoxyribonucleic Acid in Low Grade, Low Stage Untreated Prostate Cancer
26. Rectal palpation and transrectal fine needle aspiration of the prostate in the monitoring of prostate cancer: A study of 59 patients during treatment with estramustine phosphate or estrogens.
27. Cultures from Different Parts of the Urethra in Female Urethral Syndrome.
28. Antifibrinolytic Therapy with Cyklokapron in Connection with Prostatectomy: A Double Blind Study.
29. The Effect of Prophylaxis with Low Dose Heparin on Blood Coagulation Parameters
30. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
31. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
32. Clinical research done by the Scandinavian Prostate Cancer Group during the first 20 years.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.